

Cyclopia: An Epidemiologic Study in a Large Dataset From the International Clearinghouse of Birth Defects Surveillance and Research

IÊDA M. ORIOLI,^{1,2*} EMMANUELLE AMAR,³ MARIAN K. BAKKER,⁴ EVA BERMEJO-SÁNCHEZ,^{5,6,7} FABRIZIO BIANCHI,⁸ MARK A. CANFIELD,⁹ MAURIZIO CLEMENTI,¹⁰ ADOLFO CORREA,¹¹ MELINDA CSÁKY-SZUNYOGH,¹² MARCIA L. FELDKAMP,^{13,14} DANIELLE LANDAU,¹⁵ EMANUELE LEONCINI,¹⁶ ZHU LI,¹⁷ R. BRIAN LOWRY,¹⁸ PIERPAOLO MASTROIACOVO,¹⁶ MARGERY MORGAN,¹⁹ OSVALDO M. MUTCHINICK,²⁰ ANKE RISSMANN,²¹ ANNUKKA RITVANEN,²² GIOACCHINO SCARANO,²³ ELENA SZABOVA,²⁴ AND EDUARDO E. CASTILLA^{2,25,26}

¹ECLAMC (Estudo Colaborativo Latino Americano de Malformações Congênicas) at Departamento de Genética, Instituto de Biologia, Rio de Janeiro, Brazil

²INAGEMP (Instituto Nacional de Genética Médica Populacional), Rio de Janeiro, Brazil

³Rhone-Alps Registry of Birth Defects REMERA, Lyon, France

⁴Eurocat Northern Netherlands, Department of Genetics, University Medical Center Groningen, Groningen, The Netherlands

⁵Instituto de Investigación de Enfermedades Raras (IER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain

⁶ECEMC (Spanish Collaborative Study of Congenital Malformations), Centro de Investigación sobre Anomalías Congénitas (CIAC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain

⁷CIBER de Enfermedades Raras (CIBERER) (Centre for Biomedical Research on Rare Diseases), Madrid, Spain

⁸Tuscany Registry of Congenital Defects (RTDC), Epidemiology Unit, IFC-CNR, Pisa, Italy

⁹Birth Defects Epidemiology and Surveillance Branch, Texas Department of State Health Services, Texas

¹⁰Department of Pediatrics, University of Padua, Clinical Genetics Unit, Padua, Italy

¹¹Division of Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia

¹²Department of Hungarian Congenital Abnormality Registry and Surveillance, National Center for Healthcare Audit and Inspection, Budapest, Hungary

¹³Division of Medical Genetics, Department of Pediatrics, University of Utah Health Sciences Center, Salt Lake City, Utah

¹⁴Utah Birth Defect Network, Utah Department of Health, Salt Lake City, Utah

¹⁵Department of Neonatology, Soroka University Medical Center, Beer-Sheva, Israel

¹⁶Centre of the International Clearinghouse for Birth Defects Surveillance and Research, Rome, Italy

¹⁷National Center for Maternal and Infant Health, Peking University Health Science Center, Beijing, People's Republic of China

¹⁸Alberta Congenital Anomalies Surveillance System, Alberta Health and Wellness, Calgary, Alberta, Canada

¹⁹CARIS, the Congenital Anomaly Register for Wales, Singleton Hospital, Swansea, Wales

²⁰Departamento de Genética, RYVEMCE (Registro y Vigilancia Epidemiológica de Malformaciones Congénitas), Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán" Vasco de Quiroga 15, Sección XVI, Delegación Tlapan, Mexico

²¹Malformation Monitoring Centre Saxony-Anhalt, Medical Faculty Otto-von-Guericke University Magdeburg, Germany

²²The Finnish Register of Congenital Malformations, National Institute for Health and Welfare, THL, Helsinki, Finland

²³Birth Defects Campania Registry, Medical Genetics Dept, General Hospital "G. Rummo" Benevento, Italy

²⁴Slovak Teratologic Information Centre, Slovak Medical University, Bratislava, Slovak Republic

²⁵ECLAMC at CEMIC: Centro de Educación Médica e Investigación Clínica, Buenos Aires, Argentina

²⁶ECLAMC at Laboratório de Epidemiologia de Malformações Congênicas, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

Cyclopia is characterized by the presence of a single eye, with varying degrees of doubling of the intrinsic ocular structures, located in the middle of the face. It is the severest facial expression of the holoprosencephaly (HPE) spectrum. This study describes the prevalence, associated malformations, and maternal characteristics among cases with cyclopia. Data originated in 20 Clearinghouse (ICBDSR) affiliated birth defect surveillance systems, reported according to a single pre-established protocol. A total of 257 infants with cyclopia were identified. Overall prevalence was 1 in 100,000 births (95%CI: 0.89–1.14), with only one program being out of range. Across sites, there was no correlation between cyclopia prevalence and number of births ($r = -0.08$; $P = 0.75$) or proportion of elective termination of pregnancy ($r = -0.01$; $P = 0.97$). The higher prevalence of cyclopia among older mothers (older than 34) was not statistically significant. The majority of cases were liveborn (122/200; 61%) and females predominated (male/total: 42%). A substantial proportion of cyclopias (31%) were caused by chromosomal anomalies, mainly trisomy 13. Another 31% of the cases of cyclopias were associated with defects

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Grant sponsor: MCT/CNPq, Brazil; Grant numbers: 573993/2008-4, 476978/2008-4, 554755/2009-2, 306750/2009-0, 402045/2010-6; Grant sponsor: FAPERJ, Brazil; Grant numbers: E-26/102.748/2008, E-26/170.007/2008; Grant sponsor: CAPES, Brazil; Grant numbers: 1957/2009, 2799/2010; Grant sponsor: Center for Disease Control and Prevention; Grant number: 1U50DD000524-02; Grant sponsor: Instituto de Salud Carlos III (ISCIII, Ministry of Science and Innovation) of Spain; Grant sponsor: Fundación 1000 Sobre Defectos Congénitos of Spain.

*Correspondence to: Iêda M. Orioli, Departamento de Genética, Universidade Federal do Rio de Janeiro, Caixa Postal 68.011, 21944-970 Rio de Janeiro, Brazil. E-mail: orioli@centroin.com.br

DOI 10.1002/ajmg.c.30323

Published online 17 October 2011 in Wiley Online Library (wileyonlinelibrary.com).

not typically related to HPE, with more hydrocephalus, heterotaxia defects, neural tube defects, and preaxial reduction defects than the chromosomal group, suggesting the presence of ciliopathies or other unrecognized syndromes. Cyclopia is a very rare defect without much variability in prevalence by geographic location. The heterogeneous etiology with a high prevalence of chromosomal abnormalities, and female predominance in HPE, were confirmed, but no effect of increased maternal age or association with twinning was observed.

©2011 Wiley Periodicals, Inc.

KEY WORDS: cyclopia; holoprosencephaly; trisomy 13; prevalence; global; world prevalence; epidemiology; clinical

How to cite this article: Orioli IM, Amar E, Bakker MK, Bermejo-Sánchez E, Bianchi F, Canfield MA, Clementi M, Correa A, Csáky-Szunyogh M, Feldkamp ML, Landau D, Leoncini E, Li Z, Lowry RB, Mastroiacovo P, Morgan M, Mutchinick OM, Rissmann A, Ritvanen A, Scarano G, Szabova E, Castilla EE. 2011. Cyclopia: An epidemiologic study in a large dataset from the International Clearinghouse of Birth Defects Surveillance and Research. *Am J Med Genet Part C Semin Med Genet* 157:344–357.

INTRODUCTION

“Cyclopia is a congenital malformation characterized by the presence of a single eye, which usually manifests various degrees of doubling of intrinsic structures, located in the middle of the face in the place normally occupied by the root of the nose.”

With this elegant definition Sedano and Gorlin began their 1963 article about the oral manifestation of cyclopia, reporting two cyclopia patients and a literature review about the specific manifestations of cyclopia that deserves an actual reading because of its completeness. Holoprosencephaly (HPE) was also reviewed in extenso in a special issue of Part C in the *American Journal of Medical Genetics* [Muenke et al., 2010]. Thus only new pertinent information will be included here.

Usually considered as the severest gradation of facial malformation associated with HPE, cyclopia rarely is presented separately from other HPE types. Cyclopia by itself appeared in the epidemiological work of Källén et al. [1992], in the chapter in a more general work about HPE [Cohen and Sulik, 1992], and among few median anomalies in the interpretative work of O’Railly and Müller [1989]. However, there are hundreds of case reports of cyclopia in humans and in other vertebrates, besides the experimental studies in animal models causing cyclopia. This vast amount of case reports in the literature on cyclopia allows us to have an exact idea about the phenotypic variation and possible etiologies of this condition. The rarity of the condition,

however, does not allow epidemiological studies to demonstrate the risk factors and the contribution of each one to the onset of cyclopia. Using material registered by the Clearinghouse [ICBDSR, 2009] from millions of births surveyed by 20 surveillance programs worldwide, our aim here is to analyze the prevalence and possible risk factors of cyclopia.

Historical Aspects

Recent reviews of teratology and mythology by Cohen [2010b], and by Stahl and Tourame [2010] agreed with previous reviewers that real newborns with those defects existed in the origin of the mythological creatures and fantastic beings. Although there is no way to be sure of the population number at the year 800 BC in all the world, an educated guess suggested 66,000,000 [Mc Evedy and Jones, 1978], and another guess suggested a crude birth rate of 80 per 1,000 for this period (<http://www.prb.org/Articles/2002/HowManyPeopleHaveEverLivedonEarth.aspx>). If so, around the time *Odyssey* was being composed, approximately 53 cases of cyclopia were born by year, in the world population. We can speculate on how this small number of cases could have caused such an impressive impact on the people’s imagination. One possibility is that in those earlier times, the prevalence of cyclopia was higher than it is now. There are many other possibilities as there are scholarly theories of the myths. The study of the origin of the myths probably requires tools from other fields such as anthropology, psychology, sociology, or semiology.

Normal and Abnormal Development

As part of the HPE spectrum, the prosencephalon in cyclopia cases fails to develop into two hemispheres [Cohen and Sulik, 1992]. Although HPE is usually divided into alobar, semilobar, and lobar types according to severity, to the presence or not of the interhemispheric fissure and the extent of separation of both hemispheres [DeMyer and Zeman, 1963], cyclopia presents almost always as the alobar type. Only few instances of semi-lobar HPE were found in the literature [Orioli and Castilla, 2007; Dane et al., 2009]. In the alobar type there is complete or near complete lack of interhemispheric separation, single midline forebrain ventricle, absent interhemispheric fissure, falx cerebri, olfactory bulbs, and corpus callosum; and nonseparation of deep gray nuclei, as summarized in the HPE flashcards produced by Solomon et al. [2010]. Also published were detailed aspects on early pathogenesis [Shiota and Yamada, 2010], neuropathology [Hahn and Barnes, 2010], and neuroimaging [Marcorelles and Laquerriere, 2010].

In 1963, Sedano and Gorlin presented the discussion between two apparently conflicting theories, among others, to explain the pathogenesis of cyclopia. In one theory the condition is said to be caused by abnormal differentiation of the prochordal mesoderm in the central part of the developing head region. Another hypothesis states that the brain malformation is the primary anomaly. Today, it is clear that both are involved but one of the key signaling centers for the pathogenesis of HPE is

the most anterior extent of the midline mesoderm, called the prechordal plate. Several signals emanate from the prechordal plate and trigger a secondary patterning center in the ventral forebrain. Two complete reviews [Klingensmith et al., 2010; Roessler and Muenke, 2010] show that the requirement for delicate balancing of numerous key influences includes hedgehogs, fibroblast growth factors (*Fgfs*), bone morphogenic proteins (*Bmps*), retinoic acid, and canonical and noncanonical *Wnt* signaling.

England et al. [2006] labeled every cell nuclei of zebra-fish embryos with green fluorescent protein to visualize and track their movements and produced a dynamic fate map of the forebrain showing how the vertebrate eyes form. The authors also tested zebrafish embryos with two different mutations causing cyclopia showing that cyclopia in *Cyclops* (loss of *Ndr2*) results in incorporation of eye tissue into an inappropriate location within the medial neural keel (an intermediate stage between the neural plate and neural rod during the early segmentation period in the morphogenesis of the central nervous system primordium); the much reduced convergent and forward movement of lateral-posterior eye-field cells fated to the optic stalk in Silberblick cyclopia mutants (loss of *Wnt11*) results in medial-posterior eye-field cells remaining medial. These two defects of forebrain morphogenesis are temporally and spatially distinct pointing to the recognized etiologic heterogeneity of cyclopia.

Genetics and Clinical Genetics

Cyclopia is an etiologically heterogeneous condition, which can result from chromosomal defects, genetic mutations, or environmental teratogenic factors. Several important reviews address the HPE etiology, mostly by M Michael Cohen Jr., but also by Maximilian Muenke, and by Sylvie Odent and Veronique David groups. In general there is little information about the etiology of cyclopia *specifically* in those reviews because cyclopia is considered to

Cyclopia is an etiologically heterogeneous condition, which can result from chromosomal defects, genetic mutations or environmental teratogenic factors.

be the severest form of HPE [Cohen, 1989a; Muenke and Beachy, 2000; Dubourg et al., 2007].

Trisomy 13 is the most common chromosomal disorder associated with HPE. The trisomies 18 and 21 have also been described, as well as triploidy. The structural abnormalities described in the literature on 11 different chromosomes allowed the identification of 12 loci for HPE [Roessler and Muenke, 1998]. These loci are called HPE1 to HPE12 and are located in regions 21q33.3, 2p21 (*SIX3*), 7q36 (*SHH*), 18p11.3 (*TGIF*), 13q32 (*ZIC2*), 2q371–q37.3, 9q22.3 (*PTCH1*), prox 14q, 20p13, 1q42–qter (*DISP1*), 5pter, and 6q26–qter [Dubourg et al., 2007]. Only six genes (in parentheses) were assigned to the loci HPE2, HPE3, HPE4, HPE5, HPE7, and HPE10. There are no genes reported yet for the other six loci. Cohen [2006, 2010a] presented complete reviews including other genes associated with HPE; however, only the Smith–Lemli–Opitz syndrome gene, *DHCR7* on 11q12–q13, was, in the literature, associated with cyclopia in one case.

Point mutations are found in syndromes presenting HPE. The OMIM database (<http://www.ncbi.nlm.nih.gov/omim/>), visited on March 30th, 2011) presented 31 syndromes showing HPE (Table I). A careful review of them shows that only four, the dysgnathia complex (or agnathia–HPE or otocephaly) (OMIM 202650), the Pseudo-trisomy 13 syndrome (OMIM 264480), the Steinfeld syndrome (OMIM 184705); and the Smith–Lemli–Opitz syndrome (OMIM 270400), had cyclopia [Atkin, 1988; Cohen and Gorlin, 1991; Nöthen et al., 1993; Rolland

et al., 1991; Weaver et al., 2010]. Also, only these four syndromes plus osteopathia striata with cranial sclerosis (OMIM 300373) presented with the alobar type of HPE. There are descriptions of other syndromes presenting HPE in the literature, as Rubinstein–Taybi syndrome, Meckel syndrome [Hsia et al., 1971], and Martin syndrome [Martin et al., 1977], not disclosed in Table I, since they are not associated with HPE in the OMIM database (Table I).

Some cyclopia patients present with one or more unrelated congenital anomalies that are not part of the non-chromosomal syndromes cited above. Concurrence of cyclopia and sirenomelia in the same patient was reported by Martínez-Frías et al. [1998], while associations of both defects with similar epidemiological risk factors were found by Källén et al. [1992]; involvement in the same clusters was reported by Castilla et al. [2008], and sharing of a similar pathogenetic mechanism was noted by O’Railly and Müller [1989].

Classification and Nomenclature

A classical paper, whose title humorously and intelligently, two conditions rarely found in medical literature, proposed that “The face predicts the brain” was published by DeMyer et al. [1964]. However, as science has no room for poetic licenses, this publication was criticized based on reported patients which did not fit into this axiom [Olsen et al., 1997; Plawner et al., 2002], while Cohen [1989b] quantified the exceptions to the rule, concluding that the proportion of patients where the face did not predict the brain comprised from 10 to 39% of all HPE patients [Levey et al., 2010].

From the anatomic-pathological point of view, three types of HPE were described by DeMyer and Zeman [1963], in decreasing severity: alobar, semilobar, and lobar; while clinically the following types were proposed with certain degree of correspondence with the brain anatomy [DeMyer et al., 1963]: (1) Medial monophthalmia with arrhinia and proboscis (cyclopia), (2) ethmocephaly with supra-orbital proboscis,

TABLE I. Syndromes That Could Present Holoprosencephaly (HPE) Among Their Clinical Features According to OMIM (Online Mendelian Inheritance in Man)

MIM ID ^a	Syndrome	Chromosome region	Gene	Alobar type	Cyclopia	Notes
% 202650	Dysgnathia complex	—	—	Yes	Yes	Ciliopathy
264480	Pseudo-trisomy 13	—	—	Yes	Yes	AR? Microdeletion?
184705	Steinfeld	—	—	Yes	Yes	AD
# 276400	Smith–Lemli–Opitz	11q12–q13	<i>DHCR7</i>	Yes	Yes	AR
# 300373	Osteopathia striata with cranial sclerosis	Xq11.1	<i>WTX</i>	Yes	No	LXD
# 176450	Currarino	7q36	<i>HLXB9</i>	No	No	Microdeletion?
# 147791	Jacobsen, Chr. 11q deletion	11q23	—	No	No	Microdeletion
% 129900	EEC 1	7q11.2–q21.3	—	No	No	—
# 236680	Hydrolethalus 1	11q24.2	<i>HYLS1</i>	?	No	—
% 612776	Hypoglossia with situs inversus	—	—	No	No	Mild form of agnathia-HPE?
+ 187395	Teratocarcinoma derived growth factor 1	3p23–p21	<i>TDGF1</i>	No	No	Only 1 paper ^b
% 605627	Cerebrooculonasal	—	<i>PTCH?</i>	No	No	HPE7?
# 192430	Velocardiofacial	22q11.2	<i>TBX1</i>	No	No	Only 1 paper ^b
187100	Supernumerary teeth, mesiodens	—	—	No	No	—
# 147950	Kallmann 2	—	<i>FGFR1</i>	No	No	—
300706	Mental retardation XL	Xp11.2	<i>HUWE1</i>	No	No	XL
303073	Fetal akinesia XL	—	—	No	No	XL
# 253800	MDDGA4, Walker–Warburg	9q31	<i>FKTN</i>	No	No	AR, dystroglycanopathy
# 214800	Charge	8q12.1 7q21.11	<i>CHD7</i> <i>SEMA3E</i>	No	No	—
# 206900	Microphthalmia and esophageal atresia	3q26.3–q27	<i>SOX2</i>	No	No	Only one paper ^b
+ 180200	Retinoblastoma	13q14.1–q14.2	<i>RB1</i>	No	No	Del 13q14?
156810	Microgastria-limb reduction	—	—	No	No	—
300571	Hartsfield	—	—	No	No	—
601370	Genoa	—	—	No	No	AR?
306990	HPE with fetal akinesia	—	—	No	No	XL?
610680	HPE, recurrent infection, monocytosis	—	—	No	No	AD?
245552	Lambotte	—	—	No	No	—
146510	Pallister–Hall	7p13	<i>GLI3</i>	No	No	—
601357	Amelia, forebrain defects, and clefts	—	—	No	No	—
612651	Endocrine cerebroostodysplasia	6p12.3	<i>ICK</i>	No	No	—
% 600674	Microtia anotia	—	—	No	No	—

^a(+) gene with known sequence and phenotype; (#) phenotype description, molecular basis known; (%) mendelian phenotype or molecular basis unknown; (none) other, mainly phenotype with suspected mendelian basis. MIM: Online Mendelian Inheritance in Man number.

^bOnly one paper described HPE in the condition.

(3) hypotelorism, inter- or infra-orbital proboscis with single nostril (cebocephaly), (4) median cleft of the upper lip with agenesis of premaxilla (with HPE obviously).

Proboscis refers to a blind-ending tube-like structure at or near the midline of the face, and can be supra or infra orbital, synophthalmia refers to merged ocular globes with variable degrees of fused ocular structures. Synophthalmia is

Proboscis refers to a blind-ending tube-like structure at or near the midline of the face, and can be supra or infra orbital, synophthalmia refers to merged ocular globes with variable degrees of fused ocular structures.

sometimes used as cyclopia synonym as pointed out by Cohen and Sulik [1992] or to mean fused eyes in one orbit, as used by Solomon et al. [2010]. Since this is not a real fusion but rather a defect in the patterning of the eye fields, synophthalmia could be a misleading term. The origin of the word cyclopia is also controversial and it might not even mean one-eyed people.

Cyclopia represents between 10% [Orioli and Castilla, 2007] and 20% [Mastroiacovo et al., 1992] of all HPE as reported by the two largest published series, the difference being probably due to variation in phenotypic documentation.

Epidemiology (Includes Prevalence, and Risk Factors, Known or Hypothetical)

In a recent review of HPE epidemiology [Orioli and Castilla, 2010], that included prevalence and risk factors, 24 HPE published series around the world were reviewed. Two years before, HPE data from 24 of the 46 Birth Defects Registry Members of the International Clearinghouse for Birth Defects Surveillance and

Research (ICBDSR) [Leoncini et al., 2008] were also analyzed. Thirteen members of the ICBDSR also participated in the unique epidemiology study dealing only with cyclopia [Källén et al., 1992]. From these three studies, we concluded that there are several factors to explain the observed epidemiologic differences in maternal age, twinning rate and sex among the studied populations. Operational factors as the different proportions of embryos, fetuses, stillborns, and liveborns in each studied population will result in different proportions of HPE caused by chromosomal abnormalities. The younger the patients the higher the prevalence of chromosomal abnormalities. Then, variables such as maternal age and other associated with it will change accordingly.

In regard to specific environmental risk factors, Cohen and Shiota [2002] reviewed several factors, including ethyl alcohol, diabetic embryopathy, retinoic acid, and several anecdotal suggestions of teratogenic factors for HPE, including viruses, and salicylates. Orioli and Castilla [2007] confirmed in a South American series maternal diabetes and maternal flu as more prevalent in HPE than in controls. Miller et al. [2010] analyzed case patients and controls from the National Birth Defects Prevention Study and found HPE to be associated with pre-existing diabetes, aspirin use, lower education level, and use of assisted reproductive technologies. In the same issue, Johnson and Rasmussen [2010] provided a summary of nongenetic risk factors for HPE that have been investigated in case reports and case series, animal studies, and epidemiologic studies, including maternal illnesses, therapeutic and nontherapeutic exposures, nutritional factors, and sociodemographic factors.

METHODS

Birth defects surveillance programs that are part of ICBDSR were asked to provide de-identified case records following a common protocol, with information on phenotype, genetic testing, and selected demographic and prenatal

information. Further details on the methodologies can be found in Castilla and Mastroiacovo [2011] in this issue. As part of the Very Rare Defect study of the ICBDSR, 20 surveillance programs in 25 countries (10 countries represented in Estudio Colaborativo Latino Americano de Malformações Congêntas: ECLAMC), from North and South America, Europe, Israel, China and Australia provided data on cyclopia from an underlying cohort of 25.6 million births. The years represented were 1968–2006, depending on the reporting site.

Clinical and demographic data were reviewed centrally by two authors with experience in dysmorphology (IO and PM). Additional information for inclusion or exclusion of cases was also requested in a second step by one author (IO). After the identification of all chromosomal and nonchromosomal syndromes, the remaining cases with multiple congenital anomalies (MCA) were classified according to the number of unrelated defects to the HPE spectrum [Orioli and Castilla, 2007], and according to the presence of postaxial polydactyly. All cases were reported by verbatim description, and centrally classified without coding. Nevertheless in 222 of the 257 patients (86%), the defect was reported by a single word (i.e., cyclopia), therefore consisting of just a naming rather than of a real description. In 35 cases more details were provided on the HPE type, and/or the presence of proboscis, and/or the number of eyes inside the orbit.

Occurrence was expressed as total prevalence [number of live births, stillbirths and elective termination of pregnancy for fetal anomaly (ETOPFA) with cyclopia per 100,000 births] with its 95% confidence intervals (CI). For each program the expected number of cases was calculated under the hypothesis of a homogeneous prevalence among all programs. Using the expected values we calculated the exact Poisson probabilities of observing N or more cases [$P(N \geq x)$] in each registry. Maternal age-specific prevalence ratios were calculated across several clinical subtypes (isolated, MCA, and chromosomal

syndromes) with women <20 years of age serving as the referent group. Odds ratios and 95%CI were computed across clinical subtypes to examine the association of various characteristics using both isolated and MCA as a referent group. Pearson correlation was used as a measure of correlation between the prevalence of cyclopia and two variables: the number of births and the proportion of ETOPFA in each registry. The 95%CI were computed using the Poisson distribution. Statistical tests significance was set to $P < 0.05$. Statistical analyses were done with Stata software, version 10.0 [StataCorp., 2007].

RESULTS

Prevalence

The total number of births and of cyclopia cases is given in Table II for

each one of the 20 surveillance programs members of the ICBDSR. A total of 257 infants with cyclopia were identified among 25,580,661 births, giving a total prevalence of 1.0 per 100,000 births (95%CI: 0.89–1.14).

About half (54.0%) of the cases with cyclopia in this study were provided by four reporting surveillance programs: South America ECLAMC, France Central East, China Beijing, and USA Texas.

ETOPFA is not permitted for two surveillance programs (Mexico RYVEMCE: Registro y Vigilancia Epidemiológica de Malformaciones Congénitas, and South America ECLAMC). Furthermore, it was not recorded in two other surveillance programs (Spain ECEMC: Spanish Collaborative Study of Congenital Malformations, and China, Beijing), and was recorded at an unknown and


probably variable ascertainment rate in the rest.

Figure 1 compares estimates of the cyclopia prevalences with their 95%CI among the different surveillance programs. Only Hungary's prevalence's upper confidence limit was below the total prevalence of 1.0 per 100,000 births suggesting under-registration (0.26 per 100,000; CI: 0.11–0.52, $P < 0.0001$). Excluding this program, the overall prevalence of 1.10 per 100,000 is estimated for all the remaining programs, with a marginal statistically significant higher prevalence estimated in Italy North-East (1.77, CI: 1.10–2.71). There was no correlation between the cyclopia prevalence and number of births ($r = 0.08$; $P = 0.75$) or proportion of elective termination of pregnancy ($r = -0.01$; $P = 0.97$) in each surveillance program.

TABLE II. Total Prevalence (Per 100,000 Births) of Cyclopia in 20 Surveillance Programs Members of the International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR)

Surveillance program	Period	Births	Total cases	% of ETOPFA	Prevalence (per 100.000 births)	95%CI
Canada Alberta	1980–2005	1,062,483	9	0	0.85	0.39–1.61
USA Utah	1997–2004	380,706	2	50.0	0.53	0.06–1.90
USA Atlanta	1968–2004	1,283,999	13	38.5	1.01	0.54–1.73
USA Texas	1996–2002	2,054,788	25	32.0	1.22	0.79–1.80
Mexico RYVEMCE	1978–2005	1,058,885	18	NP	1.70	1.01–2.69
South America ECLAMC	1982–2006	4,556,173	55	NP	1.21	0.91–1.57
Finland	1993–2004	713,494	8	50.0	1.12	0.48–2.21
Wales	1998–2004	222,309	5	40.0	2.25	0.73–5.25
Northern Netherlands	1981–2003	369,658	3	0	0.81	0.17–2.37
Germany Saxony-Anhalt	1980–2004	355,184	3	100	0.84	0.17–2.47
Slovak Republic	2000–2005	318,257	1	100	0.31	0.01–1.75
Hungary	1980–2005	3,022,194	8	0	0.26	0.11–0.52
France Central East	1979–2004	2,500,214	30	56.7	1.20	0.81–1.71
Italy North East	1981–2004	1,186,497	21	47.6	1.77	1.10–2.71
Italy Tuscany	1992–2004	336,744	2	50.0	0.59	0.07–2.15
Italy Campania	1992–2004	643,962	2	50.0	0.31	0.04–1.12
Spain ECEMC	1980–2004	2,045,751	14	NR	0.68	0.37–1.15
Israel	1975–2005	151,562	1	0	0.66	0.02–3.68
China Beijing	1992–2005	1,927,622	29	NR	1.50	1.01–2.16
Australia Victoria	1983–2004	1,390,179	8	50.0	0.58	0.25–1.13
		25,580,661	257	40.4	1.00	0.89–1.14

RYVEMCE, Registro y Vigilancia Epidemiológica de Malformaciones Congénitas; ECLAMC, Estudio Colaborativo Latino Americano de Malformações Congénitas; ECEMC, Spanish Collaborative Study of Congenital Malformations; ETOPFA, elective termination of pregnancy for fetal anomaly; NP, not permitted; NR, not reported.



Secular Variation and Clustering of Cases

The rarity of cyclopia induces great variation in the annual frequencies within each one of the 20 programs without evident secular trends in any program. None of the programs reported an evidence of a cluster of cases.

Maternal Age

Maternal age was not specified in 9.8% of the total births and in 18.4% of the

cases with cyclopia. Maternal age was analyzed by 5-year groups in 19 programs by clinical phenotypes: isolated, MCA, and chromosomal abnormalities. Figure 2 shows that cases with chromosomal abnormalities presented a statistically significant increasing trend ($P=0.015$), as expected. The MCA case group did not show any maternal age trend, but the oldest mothers (>40 years of age) had a prevalence that was over four times the prevalence among the referent group of youngest mothers (<20 years of age) (prevalence


ratio 4.33, 95%CI: 1.16–16.12). Isolated cases did not present any maternal age effect. These results suggest that a number of undiagnosed cases of chromosomal trisomies could be present within the MCA group, but not within the isolated group.

Cases' Characteristics by Clinical Phenotype

Chromosomal syndromes. There were 79 cases with chromosomal syndromes, accounting for 31% of the cyclopias. Only 23% of total cases had an available karyotype, since karyotyping was not done or reported in all cases. Given the limited reporting on karyotypes, it is possible that the estimate of chromosomal syndromes may be higher than the 31% referred here. For example, two South American associated cases left out from the chromosomal syndromic group in the material presented here, were later on proved to have a chromosomal anomaly by multiplex ligation-dependent probe amplification (MLPA) analysis. Most of these 81 cases (79 + 2) were trisomy 13 ($n=68$; 84%), followed by trisomy 18 ($n=6$) or partial short arm monosomy ($n=3$) (subtotal $n=9$; 10%). In addition there were two cases with triploidy, one with trisomy 21, and one with a partial deletion of 7q36.

The main characteristics of chromosomal syndromes are shown in Table III. The proportion of males (0.47) did not differ from the expected in the 78 specified cases. More than half of cases are stillborn or submitted to ETOPFA, and almost 80% have low birth weight.

The comparison of the characteristics of chromosomal syndrome cases versus isolated and MCA cases are shown in Table IV, where the odds ratios of the possible "risk factors" (characteristics) with their 95%CI were computed using both isolated and MCA as a referent group. In this analysis only programs with less than 20% of unknown information were used. The occurrence of an elective termination (or ETOPFA) was approximately 3.5 times more likely among chromosomal cases than isolated



cases (OR = 3.48, 95%CI: 1.53–7.90). No significant associations were found when chromosomal cases were compared with MCA cases.

Multiple congenital anomalies (MCA). There were 81 cyclopia cases (31%) with associated defects not usually considered as part of the HPE spectrum. As mentioned before, we expected that with all cases fully analyzed for chromosomal abnormalities this proportion could be lower. When grouping these cases according the number of non-related HPE defects, 45 had only one associated defect (55%), 19 had two (24%), and 17 (21%) had three, four, or five associated defects. Most of these associated defects were similar to the ones found in the chromosomal syndromes, mainly omphalocele, anal atresia, cardiac, renal, and postaxial polydactyly. Postaxial polydactyly was present in 22/81 (27%) of the MCA cases. Different from the chromosomal syndromes, this group presented more cases with heterotaxia defects (6/81), neural tube defects (10/81), and preaxial limb reduction defects (9/81). Few nonchromosomal syndromes or associations could be suspected among the MCA cases: there were two cases with otocephaly—HPE, and two less typical examples of the dysgnathia complex, one case of prune belly, one case of VATER association with hydrocephalus,

one chondrodystrophy not further specified, and one case of cyclopia and sirenómelia in the same case. This last case, according to the partial description, probably was a case with cyclopia, sirenómelia, and acardia-acephaly. The defects presented by some of these cases are displayed in Box I.

The main characteristics of the MCA cases are shown in Table III. The proportion of male (M/T = 0.41) observed did not differ from the expected. More than half of cases were stillborn or submitted to ETOPFA.

Comparing these characteristics with the isolated cases (the comparison with chromosomal syndromes is given above) revealed only one marginal statistical association with ETOPFA (OR = 2.52; 95%CI: 1.07–5.94).

Isolated cases. The main characteristics of isolated cases are shown in Table III. The proportion of males (0.38) was statistically significant different from the expected ($\chi^2 = 6.53$; $P < 0.05$). More than half of cases were liveborn, and more than 50% have low birth weight.

DISCUSSION

Prevalence

The cyclopia prevalence 1.0 per 100,000 births (CI: 0.89–1.14) found in over 25

The cyclopia prevalence 1.0 per 100,000 births (CI: 0.89–1.14) found in over 25 million births did not differ from 1.03 found previously by Källén et al. [1992]

million births did not differ from 1.03 found previously by Källén et al. [1992] Although both series of data came from the Clearinghouse, there were data overlapping only for the Mexican, South American, Spanish, and French registries. The other 16 registries did not participate in the former work [Källén et al., 1992].

Cyclopia has been reported as between 10% and 18% of the HPE published series, as revised by Orioli and Castilla, [2010]. There are two epidemiology works about HPE using the Kyoto Collection of Embryos [Matsunaga and Shiota, 1977; Yamada et al., 2004], however only 11 embryos at Carnegie stage 8–21 had facial anomalies described in the last work. Two embryos presented complete cyclopia and three presented partially fused eyes in a single eye fissure, elevating the proportion of cyclopias among HPE to 45% in embryos.

Few studies report on the proportion of cyclopias or HPE among trisomy 13 patients. Källén et al. [1992] found 8 cyclopias in 436 (1.8%), and Wyllie et al. [1994] found one HPE among 36 trisomy 13 patients (2.8%). Considering a recent estimate of trisomy 13 prevalence of 0.14/1,000 (0.12–0.17) [Irving et al., 2011] we would have expected 3,581 patients of trisomy 13 among the 25,580,661 births, and also expected 99 cyclopias with trisomy 13. However, we detected only 68 cyclopia cases (69%) with trisomy 13.

Clustering of Cases

None of the reporting programs, including South America, reported evidence of a cluster of cases. A significant cluster

TABLE III. Characteristics of the Cases With Cyclopia

	Total cases (n = 257)		Isolated cases (n = 97)		Cases with associated malformations (n = 81)		Chromosomal syndromes (n = 79)	
	n	%	n	%	n	%	n	%
Sex								
Male	103	40.1	36	37.1	30	37.0	37	46.8
Female	143	55.6	59	60.8	43	53.1	41	51.9
Indeterminate	6	2.3	0	0.0	6	7.4	0	0.0
Missing data	5	2.0	2	2.1	2	2.5	1	1.3
Outcome								
Livebirths	122	47.5	51	52.6	35	43.2	36	45.6
Stillbirths	78	30.4	35	36.1	27	33.3	16	20.3
ETOPFA	57	22.2	11	11.3	19	23.5	27	34.2
Missing data								
Birth weight (g)^a								
<1,500	32	26.2	11	21.6	14	40.0	7	19.4
1,500–2,500	59	48.4	25	49.0	13	37.1	21	58.3
>2,500	26	21.3	14	27.5	7	20.0	5	13.9
Missing data	5	4.1	1	2.0	1	2.9	3	8.3
Gestational age (week)^a								
<32	21	17.2	9	17.7	8	22.9	4	11.1
32–36	52	42.6	19	37.3	13	37.1	20	55.6
≥37	41	33.6	20	39.2	11	31.4	10	27.8
Missing data	8	6.6	3	5.9	3	8.6	2	5.6
Parity								
0	35	13.6	18	18.6	12	14.8	5	6.3
1	93	36.2	40	41.2	29	35.8	24	30.4
2 or more	39	15.2	15	15.5	11	13.6	13	16.5
Missing data	90	35.0	24	24.7	29	35.8	37	46.8
Previous spontaneous abortions								
0	81	31.5	29	29.9	27	33.3	25	31.7
1	14	5.5	5	5.2	5	6.2	4	5.1
Missing data	162	63.0	63	65.0	49	60.5	50	63.3
Plurality								
Single	225	87.6	87	89.7	70	86.4	68	86.1
Twin	6	2.3	2	2.1	2	2.5	2	2.5
Missing data	26	10.1	8	8.3	9	11.1	9	11.4
Maternal age								
<20	18	7.0	9	9.3	5	6.2	4	5.1
20–24	63	24.5	20	20.6	28	34.6	15	19.0
25–29	63	24.5	29	29.9	17	21.0	17	21.5
30–34	47	18.3	16	16.5	12	14.8	19	24.1
35–39	28	10.9	11	11.3	8	9.9	9	11.4
≥40	8	3.1	1	1.0	4	4.9	3	3.8
Missing data	30	11.7	11	11.3	7	8.6	12	15.2
Parental age difference								
Mother same age or older	22	8.6	10	10.3	7	8.6	5	6.3
Mother 1–2 years younger	24	9.3	9	9.3	9	11.1	6	7.6
Mother 3–5 years younger	24	9.3	8	8.3	11	13.6	5	6.3
Mother >5 years younger	14	5.5	5	5.2	4	4.9	5	6.3
Missing data	173	67.3	65	67.0	50	61.7	58	73.4
Maternal education (years)								
<9	20	7.8	7	7.2	12	14.8	1	1.3
9 or more	52	20.2	26	26.8	15	18.5	11	13.9
Missing data	185	72.0	64	66.0	54	66.7	67	84.8

^aBirth weight, gestational age: the data are for live births only.

TABLE IV. Odds Ratios (OR) of the Association of the Various Characteristics of: (A) Multiple Congenital Anomalies (MCA) Cases Compared to Isolated, (B) Chromosomal Syndromes Compared to Isolated, and (C) Chromosomal Syndromes Compared to MCA Cases

	(A) MCA vs. isolated cases			(B) Chromosomal syndromes vs. isolated cases			(C) Chromosomal syndromes vs. MCA		
	Crude OR	95%CI		Crude OR	95%CI		Crude OR	95%CI	
Sex									
Male	1.00			1.00			1.00		
Female	0.87	0.47	1.63	0.68	0.37	1.24	0.77	0.41	1.47
Outcome									
Livebirths	1.00			1.00			1.00		
Stillbirths	1.12	0.58	2.18	0.65	0.31	1.34	0.58	0.26	1.25
ETOPFA	2.52	1.07	5.94	3.48	1.53	7.90	1.38	0.65	2.92
Birth weight (g) ^a									
<1,500	2.54	0.76	8.47	1.78	0.44	7.18	0.70	0.16	3.02
1,500–2,500	1.04	0.34	3.21	2.35	0.73	7.61	2.26	0.59	8.64
>2,500	1.00			1.00			1.00		
Gestational age (week) ^a									
<32	1.62	0.48	5.38	0.89	0.22	3.61	0.55	0.12	2.40
32–36	1.24	0.45	3.45	2.10	0.79	5.64	1.69	0.56	5.11
≥37	1.00			1.00			1.00		
Parity									
0	1.00			1.00			1.00		
1	0.30	0.08	1.10	0.50	0.12	2.08	1.65	0.48	5.68
2 or more	0.28	0.07	1.21	0.63	0.13	2.91	2.20	0.54	8.96
Previous spontaneous abortions									
0	1.00			1.00			1.00		
1 or more	1.17	0.18	7.79	1.50	0.25	9.11	1.28	0.26	6.34
Plurality									
Single	1.00			1.00			1.00		
Twin	1.24	0.17	9.05	1.28	0.17	9.32	1.03	0.14	7.52
Maternal age									
<20	1.00			1.00			1.00		
20–24	2.52	0.73	8.66	1.69	0.43	6.54	0.67	0.16	2.87
25–29	1.05	0.30	3.67	1.32	0.35	4.94	1.25	0.28	5.47
30–34	1.35	0.36	5.08	2.67	0.69	10.33	1.98	0.44	8.87
35–39	1.31	0.31	5.43	1.84	0.42	8.01	1.41	0.28	7.13
≥40	7.20	0.62	83.34	6.75	0.53	86.56	0.94	0.13	6.87
Parental age difference									
Mother same age or older	0.70	0.18	2.66	0.75	0.17	3.33	1.07	0.23	5.02
Mother 1–2 years younger	1.00			1.00			1.00		
Mother 3–5 years younger	1.37	0.38	5.03	0.94	0.20	4.29	0.68	0.15	2.99
Mother >5 years younger	0.80	0.16	3.99	1.50	0.30	7.53	1.87	0.35	9.98

Surveillance programs where missing data were more than 20% were excluded from the analysis

^aBirth weight, gestational age: the data are for live births only.

of sirenomelia and cyclopia in the city of Cali, Colombia [Castilla et al., 2008], was not reflected in the South American material presented in this present work since the four cases of

cyclopia born in Cali in 2005 were diluted when merged together with another 243 cases from other South American cities and periods. This exemplifies well the need for active ongoing

surveillance of the collected data, which allowed the ECLAMC program to detect the cluster within a few weeks after the fourth case of this epidemic was born. When active surveillance is

BOX 1. Defects Described in Six Cases With Cyclopia

ID	Defects	Karyotype	Diagnoses hypotheses
1	Cyclopia; alobar HPE; microcephaly; external hydrocephaly; arhinia; microstomia; prominent ears; anomalous mandible; esophageal atresia; thoracic hemivertebras; butterfly vertebras; anomalous pelvic bone; preaxial polydactyly; polyhydramnion	46,XX	OMIM # 276950 VATER with hydrocephalus
2	Cyclopia; unspecified septal ventricular defect; polycystic kidneys adult type; anomalies of hand (lobster claw hand); Arthrogryposis multiplex congenital	—	OMIM 200980 Acrorenal-mandibular with HPE
3	Cyclopia; microcephalus; jaw defect; microtia; preauricular appendage; microstomia; Meckel diverticulum; radius absent	—	OMIM % 202650 Dysgnathia complex? Ciliopathy?
4	Cyclopia; proboscis above eye; otocephaly; micropene; bilateral criptorquidia; pilonidal pit	—	OMIM % 202650 Dysgnathia complex
5	Cyclopia, partially fused eyes; proboscis above eyes; alobar HPE; arhinia; microstomia; mouth could not be open; microtia; missing first, second and thirds fingers bilaterally; feet syndactyly between second and third right toes and between third and fourth left toes; bilateral agenesis of radius; anal atresia; ambiguous genitalia; pulmonary isomerism; polisplenia; heart and abdominal organs in the midline (situs ambiguous); ovaries and uterus didelphus; one pelvic kidney with two short ureteres	46,XX	OMIM % 202650 Dysgnathia complex? Ciliopathy?
6	Cyclopia; alobar HPE; mandible agenesis; microtia grade 1; melotia; preauricular fistula; absent mouth; absent tongue; pharyngeal stenosis; hypoplastic lungs; hypoplastic adrenal glands	46,XX	OMIM % 202650 Dysgnathia complex

routinely working, the cluster is first suspected as a rumor that arises by an “alert practitioner” who was part of an epidemiology system, capable of following up on the rumor.

Maternal Age

As an important proportion of cyclopias (29%) are associated with trisomy, with an expected increased maternal age among deliveries, we expected a higher proportion of older age mothers among the cyclopia patients. However, the increased rate of cyclopias seen in the older maternal age groups (above 29 years old) in the total sample was not statistically significant. Only mothers 40 years old or above in the MCA group were in excess with respect to the mothers in the range <20. This suggests two possible explanations: (1) there is a substantial number of trisomy cases under-diagnosed among the MCA nonchromosomal group; and (2) a maternal age effect in trisomy 13 is not as important as the maternal age

effect reported in other trisomies, as trisomy 18, for example [Crider et al., 2008].

Twinning

Only 6 from 231 infants with cyclopia were twins (2.6%). This low frequency of twinning differs from the excess of twinning reported by Källén et al. [1992]. The greater size of the present sample (25.6 million births) compared with the sample size used by Källén et al. [1992] (10.1 million births) could be an explanation.

Sex

Mastroiacovo et al. [1992], Rasmussen et al. [1996], and Orioli and Castilla [2010] did not confirm the excess of females among HPE patients as described in other series. The excess of female patients among cyclopias as seen in our work among the isolated cases or in Källén et al. [1992], or in other previous HPE series [Roach et al., 1975;

Croen et al., 1996, 2000; Forrester and Merz, 2000; Chen et al., 2005] could be attributed to the excess loss of male embryos through spontaneous abortion [Rasmussen et al., 1996]. This idea was founded on studies of HPE in embryos [Matsunaga and Shiota, 1977], who showed a much higher rate of HPE than in newborns, and also on studies of fetuses with HPE, where an equal sex ratio or even a male excess could be observed [Blaas et al., 2002]. The lack of sex difference in the MCA, chromosomal syndromes and ETOPFA samples in the present work is consistent with this hypothesis, as well as the already mentioned presence of undetected chromosome syndrome patients in the MCA group.

Nonchromosomal Syndromes or Associations

In Table I are presented 31 syndromes that, with three possible exceptions, are nonchromosomal syndromes. The exceptions are pseudo-trisomy 13

(HPE-polydactyly), Currarino syndrome, and Jacobsen syndrome that could be caused by microdeletions on chromosome 13, 7q36, and 11q chromosomal regions, respectively. We scrutinized the 81 patients in the MCA group looking for examples of these syndromes without much exit. Several cases could be suspected of trisomy 13 or of pseudo-trisomy 13, mainly those with postaxial polydactyly. Few were suspected of other nonchromosomal syndromes that can be viewed in Box I.

It is out of the scope of this work to confirm the suggested diagnoses in Box I. However, the two otocephaly or agnathia-HPE patients have clear diagnoses. A recent otocephaly review [Faye-Petersen et al., 2006] shows an otocephaly prevalence around 1:70,000 births and reported that half of them present HPE. Since a conservative estimate of cyclopia among HPE is 10%, we must expect 18 patients with cyclopia-otocephaly association in our material $\{[(25,580,661/70,000)/2]/0.10\}$. The poor description observed in 86% of our cases with cyclopia could explain why we identify only 10% of the expected number of this association.

There is another possible reason to explain the few examples of syndromes we found in our MCA material. A careful review of the type of HPE associated with each one of those 31 syndromes in Table I shows that only the first four were ever associated with alobar HPE and with cyclopia: dysgnathia complex (OMIM 202650), pseudo-trisomy 13 (OMIM 264480), Steinfeld syndrome (OMIM 184705), and Smith-Lemli-Opitz syndrome (OMIM 276400).

The interesting case with cyclopia, sirenomelia, and acardia-acephaly was not found previously described in the literature. However, several patients reviewed by Siebert [2007] presented cerebral defects as cyclopia, aprosencephaly, or atelencephaly with acardiac twinning. Hypoxia-ischemia due to twin reversed arterial perfusion (TRAP) is a common explanation for these defects and probably can explain the presence of sirenomelia in our present case. Acardia-acephaly with sirenomelia

is also a combination of two very rare defects already published [Martínez-Frías, 2009; Orioli et al., 2011, this issue].

Ultimately, a new type of pathogenesis, the ciliopathies, have been proposed to explain a large number of diseases, mainly heterotaxia defects, hydrocephaly, neural tube defects, and other defects related to twinning [Hildebrandt et al., 2011]. Six patients within the MCA group of cyclopias presented with these kind of heterotaxic defects as accessory spleen, situs inversus, situs ambiguous, and lung isomerism; 6 presented with hydrocephalus, and 10 presented with NTD. With the exception of hydrocephalus, these defects were not found in excess among a South American HPE series [Orioli and Castilla, 2007]. We cannot test the statistical significance of this excess in our cyclopia sample; however, only 2 cases with bilobar lung, and no cases with hydrocephalus or NTD occurred in the chromosomal anomaly group of 79 patients. Also, only one patient with preaxial reduction defect was seen in the chromosomal group. There are several phenotypes associated with cilia dysfunction in mammals including randomization of the left-right body axis, abnormalities in neural tube closure and patterning, skeletal defects such as polydactyly, etc. A new locus for Meckel syndrome (MK8), a diagnosis that can be confounded with trisomy 13, was described [Shaheen et al., 2011], and map to *TCTN2* a paralog for Tectonic 1, which was involved in Sonic Hedgehog (*SHH*) signaling. *SHH* has been described as one of the most important genes causing HPE what reinforces the possible causal role of ciliopathies in the cyclopia causation.

Are Cyclopias Different From HPE?

Since cyclopias are rare, there are difficulties in collecting enough patients to compare epidemiologically with HPE in general. In this work a sample of 257 cyclopias could be analyzed and no important differences were demonstrated with respect to HPE [Mastroia-

covo et al., 1992; Orioli and Castilla, 2007; Orioli and Castilla, 2010]. Although the analyses of environmental factors was limited by missing data, the available data show one patient of mother with diabetes, no patients of alcoholic mothers, two patients born after threatened abortion, one using misoprostol and one not further specified, and a half dozen patients born after maternal flu or fever, among a few other gestational exposures. In general, these limited findings agree with previous HPE epidemiological data reviewed by Orioli and Castilla [2010]. There are several possible causes of HPE, but we could not highlight any of them as more important or more specific to cause cyclopia. Only the pattern of associated defects in the group MCA seems to indicate a possible role of ciliopathy disorders to explain some cases of cyclopia.

CONCLUSION

The cyclopia prevalence of 1 per 100,000 (0.89–1.14) did not differ from the previously published in the literature and was similar among most of the registries around the world. Neither the proportion of cyclopias submitted to ETOPFA, nor the number of births in each surveillance program were correlated with the cyclopia prevalence.

An important proportion of cyclopias (31%) was associated with chromosomal anomalies, mainly trisomy 13. Another 31% presented with defects that are not related to HPE. This last group also had more occurrences of other defects, namely hydrocephalus, heterotaxic defects, NTDs, and preaxial reduction defects than the chromosomal group, suggesting the presence of ciliopathies or other unrecognized syndromes. The proportion of isolated cases (38%) seems inflated, since in 86% of these cases the defect was reported by a single word (i.e., cyclopia), suggesting the practice of naming rather than providing a real description. Few nonchromosomal syndromes or associations could be suspected among the MCA cases, probably because of the paucity of the clinical descriptions.

The prevalence of all cyclopias by 5-year maternal age groups was higher among mothers in the two oldest age groups (35–39 and 40 years old or above), although this finding was not statistically significant. There was an expected increased prevalence with maternal age in the chromosomal anomaly case group. The prevalence ratio for the older maternal age group, relative to the reference age group, was higher and statistically significant in the MCA group of cyclopias, suggesting a possible contribution in this group with non-recognized cases of trisomies.

The already described excess of females in HPE was seen for the cyclopia cases, in livebirths, stillbirths, and in the total sample, without sex differences in the ETOPFA sample, MCA, and chromosomal syndrome groups.

Cyclopia differ from other very rare defects by the large contribution of chromosomal anomalies to its etiology, underlying the importance of the chromosomal examination, direct or through molecular techniques, in isolated or in associated patients. Also etiologically important are the nonchromosomal syndromes, making the accurate description of the phenotype, including cerebral imaging, and careful collection of familial history essential requirements. When possible, molecular studies should be performed since so many genes are already associated to this defect. Congenital defects registries around the world must be aware of the difficulty of gather this precious material if the verbatim description are the result of de-codification. The very rare defects deserve, inside those registries, a special treatment, with detailed phenotype descriptions and collection of all possible familial information, in order to improve future epidemiological studies.

ACKNOWLEDGMENTS

The authors are grateful to each surveillance program's staff and members for their work in collecting case data and submission to the ICBDSR Centre. This work was supported by grant from MCT/CNPq, Brazil (573993/

2008–4, 476978/2008–4, 554755/2009–2, 306750/2009–0, 402045/2010–6); FAPERJ, Brazil (E-26/102.748/2008, E-26/170.007/2008); CAPES, Brazil (1957/2009, 2799/2010). Work conducted at the Centre of the ICBDSR was supported by the Center for Disease Control and Prevention (1U50DD000524–02). This work was in part supported by Instituto de Salud Carlos III (ISCIII, Ministry of Science and Innovation) of Spain, and the Fundación 1000 Sobre Defectos Congénitos of Spain. CIBERER is an initiative of ISCIII. CIBERER is an initiative of ISCIII. Components of ECEMC's Peripheral Group are gratefully acknowledged.

REFERENCES

- Atkin JF. 1988. A new syndrome with cyclopia and trisomy 13 features. *Am J Hum Genet* 43:A36.
- Blaas HG, Eriksson AG, Salvesen KA, Isaksen CV, Christensen B, Møllerløkken G, Eik-Nes SH. 2002. Brains and faces in holoprosencephaly: Pre- and postnatal description of 30 cases. *Ultrasound Obstet Gynecol* 19:24–38.
- Castilla EE, Mastroiacovo PP. 2011. Introduction paper. *Am J Med Genet Part C* (this issue).
- Castilla EE, Mastroiacovo P, López-Camelo JS, Saldarriaga W, Isaza C, Orioli IM. 2008. Sirenomelia and cyclopia cluster in Cali, Colombia. *Am J Med Genet Part A* 146A:2626–2636.
- Chen CP, Chern SR, Lin CJ, Lee CC, Wang W, Tzen CY. 2005. A comparison of maternal age, sex ratio and associated anomalies among numerically aneuploid, structurally aneuploid and euploid holoprosencephaly. *Genet Couns* 16:49–57.
- Cohen MM Jr. 1989a. Perspectives on holoprosencephaly: Part I. Epidemiology, genetics, and syndromology. *Teratology* 40:211–235.
- Cohen MM Jr. 1989b. Perspectives on holoprosencephaly: Part III. Spectra, distinctions, continuities, and discontinuities. *Am J Med Genet* 34:271–288.
- Cohen MM Jr. 2006. Holoprosencephaly: Clinical, anatomic, and molecular dimensions. *Birth Defects Res A Clin Mol Teratol* 76:658–673.
- Cohen MM Jr. 2010a. Hedgehog signaling update. *Am J Med Genet Part A* 152A:1875–1914.
- Cohen MM Jr. 2010b. Holoprosencephaly: A mythologic and teratologic distillate. *Am J Med Genet Part C* 154C:8–12.
- Cohen MM Jr, Gorlin RJ. 1991. Pseudo-trisomy 13 syndrome. *Am J Med Genet* 39:332–335.
- Cohen MM Jr, Shiota K. 2002. Teratogenesis of holoprosencephaly. *Am J Med Genet* 109:1–15.
- Cohen MM Jr, Sulik KK. 1992. Perspectives on holoprosencephaly. Part II. Central nervous system, craniofacial anatomy, syndrome commentary, diagnostic approach, and experimental studies. *J Craniofacial Genet Dev Biol* 12:196–244.
- Crider KS, Olney RS, Cragan JD. 2008. Trisomies 13 and 18: Population prevalences, characteristics, and prenatal diagnosis, metropolitan Atlanta, 1994–2003. *Am J Med Genet Part A* 146A:820–826.
- Croen LA, Shaw GM, Lammer EJ. 1996. Holoprosencephaly: Epidemiologic and clinical characteristics of a California population. *Am J Med Genet* 64:465–472.
- Croen LA, Shaw GM, Lammer EJ. 2000. Risk factors for cytogenetically normal holoprosencephaly in California: A populationbased case-control study. *Am J Med Genet* 90:320–325.
- Dane B, Dane C, Aksoy F, Yayla M. 2009. Semilobar holoprosencephaly with associated cyclopia and radial aplasia: First trimester diagnosis by means of integrating 2D–3D ultrasound. *Arch Gynecol Obstet* 280:647–651.
- DeMyer W, Zeman W. 1963. Alobar holoprosencephaly (arhinencephaly) with median cleft lip and palate: Clinical, electroencephalographic and nosologic considerations. *Confin Neurol* 23:1–36.
- DeMyer WE, Zeman W, Palmer CG. 1963. Familial alobar holoprosencephaly (arhinencephaly) with median cleft lip and palate: Report of patient with 46 chromosomes. *Neurology* 13:913–918.
- DeMyer W, Zeman W, Palmer CG. 1964. The face depicts the brain: Diagnostic significance of median facial anomalies for holoprosencephaly (arhinencephaly) with median cleft lip and palate. *Pediatrics* 34:256–263.
- Dubourg C, Bendavid C, Pasquier L, Henry C, Odent S, David V. 2007. Holoprosencephaly. *Orphanet J Rare Dis* 2:8 DOI:10.1186/1750-1172-2-8.
- England SJ, Blanchard GB, Mahadevan L, Adams RJ. 2006. A dynamic fate map of the forebrain shows how vertebrate eyes form and explains two causes of cyclopia. *Development* 133:4613–4617.
- Faye-Petersen O, David E, Rangwala N, Seaman JP, Hua Z, Heller DS. 2006. Otocephaly: Report of five new cases and a literature review. *Fetal Pediatr Pathol* 25:277–296.
- Forrester MB, Merz RD. 2000. Epidemiology of holoprosencephaly in Hawaii, 1986–97. *Paediatr Perinat Epidemiol* 14:61–63.
- Hahn JS, Barnes PD. 2010. Neuroimaging advances in holoprosencephaly: Refining the spectrum of the midline malformation. *Am J Med Genet Part C Semin Med Genet* 154C:120–132.
- Hildebrandt F, Benzing T, Katsanis N. 2011. Ciliopathies. *N Engl J Med* 364:1533–1543.
- Hsia YE, Bratu M, Herboldt A. 1971. Genetics of the Meckel syndrome (dysencephalia splanchnocystica). *Pediatrics* 48:237–247.
- ICBDSR International Clearinghouse for Birth Defects Surveillance and Research. 2009. Annual Report 2007. Roma and website: <http://www.icbdsr.org>, November 27, 2009.
- Irving C, Richmond S, Wren C, Longster C, Embleton ND. 2011. Changes in fetal

- prevalence and outcome for trisomies 13 and 18: A population-based study over 23 years. *J Matern Fetal Neonatal Med* 24:137–141.
- Johnson CY, Rasmussen SA. 2010. Non-genetic risk factors for holoprosencephaly. *Am J Med Genet Part C* 154C:73–85.
- Källén B, Castilla EE, Lancaster PA, Mutchinick O, Knudsen LB, Martínez-Frías ML, Mastroiacovo P, Robert E. 1992. The cyclops and the mermaid: An epidemiological study of two types of rare malformation. *J Med Genet* 29:30–35.
- Klingensmith J, Matsui M, Yang Y-P, Anderson RM. 2010. Roles of bone morphogenetic protein signaling and its antagonism in holoprosencephaly. *Am J Med Genet Part C* 154C:43–51.
- Leoncini E, Baranello G, Orioli IM, Annerén G, Bakker M, Bianchi F, Bower C, Canfield MA, Castilla EE, Cocchi G, Correa A, De Vigan C, Doray B, Feldkamp ML, Gatt M, Irgens LM, Lowry RB, Maraschini A, McDonnell R, Morgan M, Mutchinick O, Poetsch S, Riley M, Ritvanen A, Gnansia ER, Scarano G, Sipek A, Tenconi R, Mastroiacovo P. 2008. Frequency of holoprosencephaly in the International Clearinghouse Birth Defects Surveillance Systems: Searching for population variations. *Birth Defects Res A Clin Mol Teratol* 82:585–591.
- Levey EB, Stashinko E, Clegg NJ, Delgado MR. 2010. Management of children with holoprosencephaly. *Am J Med Genet Part C Semin Med Genet* 154C:183–190.
- Marcorelles P, Laquerriere A. 2010. Neuropathology of holoprosencephaly. *Am J Med Genet Part C* 154C:109–119.
- Martin AO, Perrin JC, Muir WA, Ruch E, Schafer IA. 1977. An autosomal dominant midline cleft syndrome resembling familial holoprosencephaly. *Clin Genet* 12:65–72.
- Martínez-Frías ML. 2009. Epidemiology of acephalus/acardius monozygotic twins: New insights into an epigenetic causal hypothesis. *Am J Med Genet Part A* 149A:640–649.
- Martínez-Frías ML, Garcia A, Bermejo E. 1998. Cyclopia and sirenomelia in a liveborn infant [letter]. *J Med Genet* 35:263–264.
- Mastroiacovo P, Botto LD, Cavalcanti DP, Zampino G, Serafini MA. 1992. Epidemiological and genetic study of holoprosencephaly in 106 cases observed in the Italian Multicentric Registry 1978–1989. Paper presented at Proceedings of the 1st International Meeting of the Genetic and Reproductive Epidemiology Research Society (GRERS), Roma.
- Matsunaga E, Shiota K. 1977. Holoprosencephaly in human embryos: Epidemiologic studies of 150 cases. *Teratology* 16:261–272.
- Mc Evedy C, Jones R. 1978. Atlas of world population history. Middlesex: Penguin.
- Miller EA, Rasmussen SA, Siega-Riz AM, Frias JL, Honein MA, The National Birth Defects Prevention Study. 2010. Risk factors for non-syndromic holoprosencephaly in the National Birth Defects Prevention Study. *Am J Med Genet Part C* 154C:62–72.
- Muenke M, Beachy PA. 2000. Genetics of ventral forebrain development and holoprosencephaly. *Curr Opin Genet Dev* 10:262–269.
- Muenke M, Solomon BD, Odent S. 2010. Introduction to the American Journal of Medical Genetics Part C on holoprosencephaly. *Am J Med Genet Part C* 154C:1–2.
- Nöthen MM, Knöpfle G, Födisch HJ, Zerres K. 1993. Steinfeld syndrome: Report of a second family and further delineation of a rare autosomal dominant disorder. *Am J Med Genet* 46:467–470.
- O'Railly R, Müller F. 1989. Interpretation of some median anomalies as illustrated by cyclopia and symmelia. *Teratology* 40:409–421.
- Olsen C, Hughes J, Youngblood L, Sharpe-Stimac M. 1997. Epidemiology of holoprosencephaly and phenotypic characteristics of affected children: New York State, 1984–1989. *Am J Med Genet* 73:217–226.
- Orioli IM, Castilla EE. 2007. Clinical epidemiologic study of holoprosencephaly in South America. *Am J Med Genet Part A* 143A:3088–3099.
- Orioli IM, Castilla EE. 2010. Epidemiology of holoprosencephaly: Prevalence and risk factors. *Am J Med Genet Part C* 154C:13–21.
- Orioli IM, Amar E, Arteaga-Vazquez J, Bakker MK, Bianca S, Botto LD, Clementi M, Correa A, Csaky-Szunyogh M, Leoncini E, López-Camelo JS, Li Z, Lowry RB, Marengo L, Martínez-Frías ML, Mastroiacovo P, Morgan M, Pierini A, Ritvanen A, Scarano G, Szabova E, Castilla EE. 2011. Sirenomelia: An epidemiologic study in a large dataset from the International Clearinghouse of Birth Defects Surveillance and Research, and literature review. *Am J Med Genet Part C* (this issue).
- Plawner LL, Delgado M, Miller V, Levey E, Kinsman S, Barkovich AJ, Simon E, Clegg N, Sweet V, Stashinko E, Hahn JS. 2002. Neuroanatomy of holoprosencephaly as predictor of function: Beyond the face predicting the brain. *Neurology* 59:1058–1066.
- Rasmussen SA, Moore CA, Khoury MJ, Cordero JF. 1996. Descriptive epidemiology of holoprosencephaly and arhinencephaly in metropolitan Atlanta, 1968–1992. *Am J Med Genet* 66:320–333.
- Roach E, Demyer W, Conneally PM, Palmer C, Merritt AD. 1975. Holoprosencephaly: Birth data, genetic and demographic analyses of 30 families. *Birth Defects Orig Artic Ser* 11:294–313.
- Roessler E, Muenke M. 1998. Holoprosencephaly: A paradigm for the complex genetics of brain development. *J Inherit Metab Dis* 21:481–497.
- Roessler E, Muenke M. 2010. The molecular genetics of holoprosencephaly. *Am J Med Genet Part C* 154C:52–61.
- Rolland M, Sarramon MF, Bloom MC. 1991. Astomia-agnathia-holoprosencephaly association. Prenatal diagnosis of a new case. *Prenat Diagn* 11:199–203.
- Sedano HO, Gorlin RJ. 1963. The oral manifestations of cyclopia. Review of the literature and report of two cases. *Oral Surg Oral Med Oral Pathol* 16:823–838.
- Shaheen R, Faqieh E, Seidahmed MZ, Sunker A, Alali FE, Khadijah A, Alkuraia FS. 2011. A TCTN2 mutation defines a novel Meckel Gruber syndrome locus. *Hum Mutat* 32:573–578.
- Shiota K, Yamada S. 2010. Early pathogenesis of holoprosencephaly. *Am J Med Genet Part C* 154C:22–28.
- Siebert JR. 2007. Cyclopia, aprosencephaly, and acardiac twinning: Is hypoxia-ischemia a unifying mechanism? *Am J Med Genet Part A* 143A:3100–3106.
- Solomon BD, Pineda-Alvarez DE, Mercier S, Raam MS, Odent S, Muenke M. 2010. Holoprosencephaly flashcards: A summary for the clinician. *Am J Med Genet Part C* 154C:3–7.
- Stahl A, Tourame P. 2010. De la tératologie aux monstres de la mythologie et des le gendes antiques (From teratology to mythology: Ancient legends). *Arch Pédiatr* 17:1716–1724. [French.]
- StataCorp. 2007. Stata Statistical Software: Release 10. College Station, TX: StataCorp LP.
- Weaver DD, Solomon BD, Akin-Samson K, Kelley RI, Muenke M. 2010. Cyclopia (synophthalmia) in Smith-Lemli-Opitz syndrome: First reported case and consideration of mechanism. *Am J Med Genet Part C* 154C(1):142–145.
- Wyllie JP, Wright MJ, Burn J, Hunter S. 1994. Natural history of trisomy 13. *Arch Dis Child* 71:343–345.
- Yamada S, Uwabe C, Fujii S, Shiota K. 2004. Phenotypic variability in human embryonic holoprosencephaly in the Kyoto Collection. *Birth Defects Res A Clin Mol Teratol* 70:495–508.